Compare AbbVie Inc (ABBV) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Illinois Tool Works Inc. — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Illinois Tool Works Inc. trades at $264.47 (market cap $77.99B). The key difference: AbbVie Inc is far larger — about 5.8× Illinois Tool Works Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | ITW | |
|---|---|---|
Market Cap | $449.91B | $77.99B |
Sector | Health | Industrials |
52-Week High | $261.07 | $299.60 |
52-Week Low | $184.85 | $241.07 |
Enterprise Value | $513.38B | $86.31B |
Dividend Yield | 2.72% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
ITW trades at $271.09, down 0.61% on the day, with a bullish technical signal from moving averages and ADX indicators. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights product upgrades from its Miller Electric division and a declared quarterly dividend of $1.61.
Outlook remains positive with raised 2026 EPS guidance, though valuation ratios like P/E of 25.47 suggest premium pricing. Risks include high debt levels and sensitivity to industrial demand cycles. Analyst consensus price target of $284.50 implies modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
